Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)
NCT01371461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 390
Last updated 2017-06-08
Summary
Overall improvement, severities and changes of specific clinical symptoms were surveyed in outpatients with depression or in a depressed state to evaluate the efficacy and safety of PAXIL tablets in patients in whom the PAXIL dose was increased and those treated with a constant dose.
Conditions
- Mental Disorders
Interventions
- DRUG
-
Paroxetine
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-01-31
- Primary Completion
- 2004-07-31
- Completion
- 2004-10-31
More Related Trials
-
Major Depressive Disorder Study In Adults
NCT00049972 ·Status: COMPLETED ·Phase: PHASE4
-
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
NCT00413023 ·Status: COMPLETED ·Phase: PHASE2
-
Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)
NCT00812812 ·Status: TERMINATED ·Phase: PHASE4
-
A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria
NCT00516113 ·Status: COMPLETED ·Phase: PHASE4
-
Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)
NCT00866294 ·Status: COMPLETED ·Phase: PHASE3
-
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
NCT00073411 ·Status: COMPLETED ·Phase: PHASE3
-
Antidepressant Trial With P2X7 Antagonist JNJ-54175446
NCT04116606 ·Status: UNKNOWN ·Phase: PHASE2
-
Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects
NCT01318031 ·Status: COMPLETED ·Phase: PHASE1
-
Duloxetine Versus Paroxetine for Major Depression
NCT00489775 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of GW856553X For the Treatment of Depression
NCT00569062 ·Status: TERMINATED ·Phase: PHASE2
-
Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)
NCT02051413 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
NCT00825058 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
NCT02498392 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
NCT03559192 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Orcinoside With Placebo in Treatment of MDD
NCT02191384 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder
NCT03374475 ·Status: COMPLETED ·Phase: PHASE1
-
Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder
NCT01119430 ·Status: TERMINATED ·Phase: PHASE2
-
A Local Register Study For Major Depression Of Paroxetine Controlled Release
NCT00368303 ·Status: COMPLETED ·Phase: PHASE3
-
GSK372475 PK Study in Healthy Volunteers
NCT00728208 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
NCT00536471 ·Status: COMPLETED ·Phase: PHASE4
-
A Study in Depression and Associated Painful Physical Symptoms
NCT01070329 ·Status: COMPLETED ·Phase: PHASE4
-
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
NCT00057213 ·Status: COMPLETED ·Phase: PHASE2
-
Depression Study In Elderly Patients
NCT00067444 ·Status: COMPLETED ·Phase: PHASE3
-
Pentoxifylline for Treatment of Resistant Major Depression
NCT05324735 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
NCT01500200 ·Status: COMPLETED ·Phase: PHASE2